These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 31996670)

  • 21. MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice.
    Göbel C; Godbole S; Schoof M; Holdhof D; Kresbach C; Loose C; Neumann J; Schüller U
    Acta Neuropathol Commun; 2023 Nov; 11(1):174. PubMed ID: 37919824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
    Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
    Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
    Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
    Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas.
    Adamson DC; Shi Q; Wortham M; Northcott PA; Di C; Duncan CG; Li J; McLendon RE; Bigner DD; Taylor MD; Yan H
    Cancer Res; 2010 Jan; 70(1):181-91. PubMed ID: 20028867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma.
    Shishido K; Purvis IJ; Velpula KK; Venkataraman S; Vibhakar R; Asuthkar S
    Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
    Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
    J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification.
    Ćwiek P; Leni Z; Salm F; Dimitrova V; Styp-Rekowska B; Chiriano G; Carroll M; Höland K; Djonov V; Scapozza L; Guiry P; Arcaro A
    Oncotarget; 2015 Jan; 6(1):116-29. PubMed ID: 25402633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.
    Swartling FJ; Savov V; Persson AI; Chen J; Hackett CS; Northcott PA; Grimmer MR; Lau J; Chesler L; Perry A; Phillips JJ; Taylor MD; Weiss WA
    Cancer Cell; 2012 May; 21(5):601-613. PubMed ID: 22624711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Proteogenomic Approach to Understanding MYC Function in Metastatic Medulloblastoma Tumors.
    Staal JA; Pei Y; Rood BR
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells.
    Kawauchi D; Ogg RJ; Liu L; Shih DJH; Finkelstein D; Murphy BL; Rehg JE; Korshunov A; Calabrese C; Zindy F; Phoenix T; Kawaguchi Y; Gronych J; Gilbertson RJ; Lichter P; Gajjar A; Kool M; Northcott PA; Pfister SM; Roussel MF
    Oncogene; 2017 Sep; 36(37):5231-5242. PubMed ID: 28504719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
    Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
    J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
    Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
    Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cells.
    Bunt J; Hasselt NE; Zwijnenburg DA; Hamdi M; Koster J; Versteeg R; Kool M
    Int J Cancer; 2012 Jul; 131(2):E21-32. PubMed ID: 21964830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
    von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
    BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation.
    Su X; Gopalakrishnan V; Stearns D; Aldape K; Lang FF; Fuller G; Snyder E; Eberhart CG; Majumder S
    Mol Cell Biol; 2006 Mar; 26(5):1666-78. PubMed ID: 16478988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma.
    Fiaschetti G; Schroeder C; Castelletti D; Arcaro A; Westermann F; Baumgartner M; Shalaby T; Grotzer MA
    Acta Neuropathol Commun; 2014 Apr; 2():39. PubMed ID: 24708907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An animal model of MYC-driven medulloblastoma.
    Pei Y; Moore CE; Wang J; Tewari AK; Eroshkin A; Cho YJ; Witt H; Korshunov A; Read TA; Sun JL; Schmitt EM; Miller CR; Buckley AF; McLendon RE; Westbrook TF; Northcott PA; Taylor MD; Pfister SM; Febbo PG; Wechsler-Reya RJ
    Cancer Cell; 2012 Feb; 21(2):155-67. PubMed ID: 22340590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leading medulloblastoma to a differentiation end.
    Nör C; Ramaswamy V
    Cancer Cell; 2024 Aug; 42(8):1331-1333. PubMed ID: 39137724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional analysis of HOXA10 and HOXB4 in human medulloblastoma cell lines.
    Bonfim-Silva R; Ferreira Melo FU; Thomé CH; Abraham KJ; De Souza FAL; Ramalho FS; Machado HR; De Oliveira RS; Cardoso AA; Covas DT; Fontes AM
    Int J Oncol; 2017 Dec; 51(6):1929-1940. PubMed ID: 29039487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
    Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
    Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.